Quest Diagnostics Inc vs Novartis AG — how do they compare? Quest Diagnostics Inc trades at $237.5 (market cap $26.21B), while Novartis AG trades at $152.4 (market cap $295.37B). The key difference: Novartis AG is far larger — about 11.3× Quest Diagnostics Inc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| DGX | NVS | |
|---|---|---|
Market Cap | $26.21B | $295.37B |
Sector | Health | Health |
52-Week High | $238.50 | $168.62 |
52-Week Low | $173.49 | $119.31 |
Enterprise Value | $31.97B | $336.69B |
Dividend Yield | 1.45% | 3.07% |
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →